Table 1 |
||
|
Biomarker change by antihormone type and menopause |
||
|
Biomarker and menopause status |
Tamoxifen |
Aromatase inhibitor |
|
|
||
|
Breast density premenopause |
Marked |
NA |
|
Breast density postmenopause |
Minimal |
? |
|
Serum IGF-1/IGFBP3 ratio |
Decrease |
No change |
|
Serum E2 premenopause |
Large increase |
NA |
|
Serum E2 postmenopause (no HRT) |
Slight increase |
Decrease |
|
Reverse atypia in 6 to 12 months |
Doubtful |
Doubtful |
|
|
||
|
E2, oestradiol; IGF, insulin-like growth factor; HRT, hormonre replacement therapy; IGFBP, IGF-1 binding protein; NA, not applicable. |
||
|
Fabian Breast Cancer Research 2007 9(Suppl 2):S18 doi:10.1186/bcr1816 |
||